Log in to search using one of your social media accounts:

 

First-Line Doxorubicin for Advanced Sarcoma, Not Combo? First-Line Doxorubicin for Advanced Sarcoma, Not Combo?
Doxorubicin should remain first-line therapy for patients with soft-tissue sarcoma, conclude trialists who compared it with a gemcitabine and docetaxel combination.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 27, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer
(European Society for Medical Oncology) Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase III RANGE trial presented today at the ESMO 2017 Congress in Madrid to be published in The Lancet. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 10, 2017 Category: Cancer & Oncology Source Type: news

New data confirms superiority of docetaxel based triplet therapy in gastric cancer
(European Society for Medical Oncology) The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2017 Category: International Medicine & Public Health Source Type: news

Management of Castration-Resistant, Taxane-Resistant Prostate Cancer
Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2017 Category: Cancer & Oncology Authors: Tomasz M. Beer, MD Tags: Genitourinary Cancers Oncology Journal Prostate Cancer Source Type: news

Cabazitaxel Not Superior to Docetaxel in Metastatic CRPC
Two different doses of cabazitaxel failed to show superiority with regard to overall survival over docetaxel as first-line treatment for patients with metastatic castration-resistant prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 8, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers News Prostate Cancer Source Type: news

A mathematical crystal ball gazes into future of prostate cancer treatment
(University of Colorado Anschutz Medical Campus) Using open data from four previously conducted clinical trials, teams of international researchers designed mathematical models predicting the likelihood that a patient will discontinue docetaxel treatment due to adverse events. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - August 4, 2017 Category: International Medicine & Public Health Source Type: news

Docetaxel-Based Triplet New Standard in Gastric Cancer
Perioperative chemotherapy with a docetaxel-based triplet should be considered the new standard of care for resectable gastric or GEJ adenocarcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 21, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Gastrointestinal Cancer News Source Type: news

Does ERG Expression Predict Docetaxel Benefit in Prostate Cancer?
Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy, according to analyses of two phase III clinical trials. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Prostate Cancer News Source Type: news

Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Randomized, placebo-controlled study confirms ramucirumab, in combination with docetaxel, significantly extended progression-free survival (PFS) in previously treated patients with locally advanced or unresectable or metastatic urothelial carcinoma INDI... Biopharmaceuticals, Oncology Eli Lilly, CYRAMZA, ramucirumab, urothelial carcinoma, bladder cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 31, 2017 Category: Pharmaceuticals Source Type: news

Adding Selumetinib to Docetaxel Doesn ’ t Up PFS in NSCLC
No improvement in progression - free survival for previously treated advanced KRAS - mutant NSCLC (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 10, 2017 Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news

MEK Inhibitor Adds No Value in Treatment of KRAS-Mutant NSCLC
Adding selumetinib to docetaxel does not provide any significant benefit over docetaxel alone for patients previously treated for advanced KRAS-mutant non –small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Lung Cancer News Source Type: news

Blood test may lead to targeted therapy for prostate cancer
Conclusion Genetic testing is becoming more common in cancer treatment as a way of tailoring treatment to the individual cancer. It's already used in breast cancer, for example. This test could help identify which men that have not responded to hormone treatment are most likely to benefit from two of the newer prostate cancer drugs. It is good news, because men could then be spared treatment that is unlikely to help them, and directed towards more suitable treatment options. Also, both of these newer drugs are very expensive, so a suitable test could save the NHS a great deal of money. Meanwhile, those men who are likely t...
Source: NHS News Feed - May 5, 2017 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Vinorelbine, Pertuzumab, and Trastuzumab for Breast Cancer Vinorelbine, Pertuzumab, and Trastuzumab for Breast Cancer
Is the combination of vinorelbine with dual HER2-targeted therapy a good first-line option for patients needing an alternative to docetaxel?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Metformin Use Does Not Increase Prostate Cancer Survival
Drug given in combination with docetaxel chemotherapy in patients with metastatic disease (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 11, 2017 Category: Cancer & Oncology Tags: Endocrinology, Oncology, Pharmacy, Urology, Journal, Source Type: news

Custirsen Does Not Improve Overall Survival in mCRPC
The addition of custirsen to docetaxel and prednisone failed to improve overall survival among patients with metastatic castration-resistant prostate cancer in a phase III trial. (Source: CancerNetwork)
Source: CancerNetwork - March 31, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers News Prostate Cancer Source Type: news

Japan clears Novocure ’ s 2nd gen Optune device
Novocure (NSDQ:NVCR) said today it won approval from the Japanese Ministry of Health, Labour and Welfare for its 2nd-gen Optune device. The Optune is a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit cancer cell replication and cause cancer cell death, the St. Helier, N.J.-based company said. The next-generation device is smaller, lighter and features a tumor treating field generator that is less than half the weight and size of the 1st-generation Optune system, NovoCure said. “The MHLW’s approval ...
Source: Mass Device - March 21, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Oncology Regulatory/Compliance NovoCure Source Type: news

Fatal Neutropenic Enterocolitis With Docetaxel in France Fatal Neutropenic Enterocolitis With Docetaxel in France
Five fatal cases of neutropenic enterocolitis associated with a generic version of docetaxel have led one cancer centre to swap the drug for paclitaxel.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 20, 2017 Category: Cancer & Oncology Tags: Internal Medicine News Source Type: news

Novocure enrolls 1st patient in TTFields, chemo treatment lung cancer phase III trial
Novocure (NSDQ:NVCR) said today it enrolled the 1st patient in the phase 3 pivotal Lunar trial of its Tumor Treating Field technology for treating patients with advanced non-small cell lung cancer who have failed platinum-based therapy. The prospective, randomized 512-patient trial from the St. Helier, N.J.-based company aims to test the safety and efficacy of its TTFields technology in combination with standard of care treatments of immune checkpoint inhibitors or docetaxel. Get the full story at our sister site, Drug Delivery Business News. The post Novocure enrolls 1st patient in TTFields, chemo treatment...
Source: Mass Device - February 15, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Oncology NovoCure Source Type: news

Docefrez (docetaxel) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 25, 2017 Category: Drugs & Pharmacology Source Type: news

Docetaxel, zoledronic acid not cost  effective for prostate cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 31, 2016 Category: Drugs & Pharmacology Source Type: news

Mesothelioma Trial for Nintedanib Shows Positive Results
Researchers have reported more promising results from an international, multicenter phase II clinical trial of the drug nintedanib, moving it another step closer to standard-of-care treatment for pleural mesothelioma. Nintedanib is a small-molecule enzyme inhibitor being studied as a way to increase the effectiveness of chemotherapy on mesothelioma and certain types of lung cancer. Researchers presented the results earlier this month at the World Conference on Lung Cancer in Vienna, Austria. The randomized clinical trial treated mesothelioma patients with a placebo and chemotherapy (pemetrexed/cisplatin) or nintedanib and ...
Source: Asbestos and Mesothelioma News - December 22, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: chemotherapy clinical trial chemotherapy for mesothelioma extending mesothelioma survival mesothelioma treatment nintedanib Source Type: news

Increased TIL Levels Associated With Better Outcomes in HER2-Positive Breast Cancer
A higher quantity of stromal tumor-infiltrating lymphocytes (TILs) was associated with better overall survival in patients with advanced HER2-positive breast cancer treated with either pertuzumab or placebo, along with trastuzumab and docetaxel. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Atezolizumab Extends Overall Survival in Advanced NSCLC
(MedPage Today) -- Median 4 months longer than with docetaxel (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 13, 2016 Category: Primary Care Source Type: news

Atezolizumab Improved Overall Survival Across Subgroups With NSCLC
The PD-L1 inhibitor atezolizumab significantly improved overall survival compared with docetaxel across subgroups of patients with non –small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 7, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Lung Cancer News Source Type: news

Pembrolizumab in lung cancer: Indication of considerable added benefit
(Institute for Quality and Efficiency in Health Care) Advantages, e.g. in mortality, notably outweigh the disadvantages in some side effects in comparison with docetaxel. An added benefit over best supportive care is not proven. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 22, 2016 Category: Global & Universal Source Type: news

Chemical compound holds promise as cancer treatment with fewer side effects than traditional chemotherapy
A synthetic version of a rare toxin produced by a sea creature appears to hold promise for treating many different types of cancer while minimizing the harmful side effects of widely used chemotherapy drugs.A study published today in the journal Science  Translational Medicine describes research on a substance called diazonamide, which prevents cell division, and was isolated from a marine animal calledDiazona angulata.Led by Patrick Harran, UCLA ’s Donald J. and Jane M. Cram Professor of Organic Chemistry, researchers produced a synthetic form of diazonamide that, in rodents, appears to be effective in fighting...
Source: UCLA Newsroom: Health Sciences - November 16, 2016 Category: Universities & Medical Training Source Type: news

Docetaxel-Based Chemo Promising in Stomach and Esophageal Cancer Docetaxel-Based Chemo Promising in Stomach and Esophageal Cancer
Perioperative treatment with docetaxel-based triplet chemotherapy may beat anthracycline-based triplet chemotherapy in resectable gastric or gastro-esophageal junction adenocarcinoma, according to a randomized clinical trial.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 3, 2016 Category: Surgery Tags: Hematology-Oncology News Source Type: news

New Lung Cancer Study May Improve Mesothelioma Therapy
New insight into the gene responsible for the most aggressive subtype of non-small cell lung cancer (NSCLC) could bring hope for mesothelioma patients. Researchers from UT Southwestern Medical Center identified a new way to target lung cancer through the Kirsten rat sarcoma viral oncogene homolog, also known as the KRAS gene. Tumors that carry a mutation in this gene account for about 30 percent of lung cancer cases, which are usually aggressive with a poor prognosis. Prior to the study, scientists had difficulty targeting the gene. The KRAS gene produces proteins called K-Ras, which influence cell division. Mutations i...
Source: Asbestos and Mesothelioma News - September 28, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: asbestos exposure asbestos lung cancer KRAS lung cancer KRAS mutation lung cancer study mesothelioma clinical trial mesothelioma research mesothelioma treatment Source Type: news

Nivolumab in advanced lung cancer: Indication of major added benefit
Patients with advanced nonsquamous NSCLC who have already undergone chemotherapy survive longer with the drug Nivolumab than with docetaxel. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 18, 2016 Category: Science Source Type: news

Nivolumab in advanced lung cancer: Indication of major added benefit
(Institute for Quality and Efficiency in Health Care) Patients with advanced nonsquamous NSCLC who have already undergone chemotherapy survive longer with the drug than with docetaxel. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 18, 2016 Category: Global & Universal Source Type: news

AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
BOULDER, Colo., Aug. 9, 2016 -- (Healthcare Sales & Marketing Network) -- AstraZeneca (LON/STO/NYSE: AZN) today announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-li... Biopharmaceuticals, Oncology AstraZeneca, Array BioPharma, selumetinib, NSCLC, KRAS (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 9, 2016 Category: Pharmaceuticals Source Type: news

NICE recommends VARGATEF < sup > ® < /sup > (nintedanib*) in combination with docetaxel as an option for patients with non-small cell lung cancer of adenocarcinoma histology within its licensed indication
NICE recommends VARGATEF ® (nintedanib*) in combination with docetaxel as an option for patients with non-small cell lung cancer of adenocarcinoma histology within its licensed indication (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

VARGATEF < sup > ® < /sup > plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compared to docetaxel alone
VARGATEF ® plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compared to docetaxel alone (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Nivolumab cost-effectiveness improves by selecting non-squamous NSCLC PD-L1+ patients
(International Association for the Study of Lung Cancer) Nivolumab (NIV), a checkpoint inhibitor approved for all squamous and non-squamous non-small cell lung cancer (NSCLC) patients in 2015, is not cost-effective when compared to treatment with docetaxel (DOC), chemotherapy medication. However, a Swiss analysis showed the cost-effectiveness of NIV is improved when patients are treated with NIV based on PD-L1 positivity (PD-L1+), or if there is a reduction in dose or drug price. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 13, 2016 Category: Global & Universal Source Type: news

ASCO: Intermittent Docetaxel May be Option in mCRPC (CME/CE)
(MedPage Today) -- Chemo breaks well tolerated, with good 1-year survival (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - June 9, 2016 Category: Journals (General) Source Type: news

ASCO: Docetaxel Still King in Chemo-Naive mCRPC Patients (CME/CE)
(MedPage Today) -- Cabazitaxel remains a second-line therapy after docetaxel (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - June 9, 2016 Category: Journals (General) Source Type: news

ASCO: Docetaxel Falls Short in High-Risk Prostate Cancer (CME/CE)
(MedPage Today) -- Adjuvant therapy didn't improve outcome (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - June 8, 2016 Category: Journals (General) Source Type: news

Bayer and Orion Expand Clinical Development Program for BAY-1841788 (ODM-201) in Prostate Cancer
Phase III study to be initiated in metastatic hormone-sensitive prostate cancer assessing the androgen-receptor antagonist in combination with standard androgen deprivation therapy and the chemotherapy docetaxel Start of patient enrollment expected towa... Biopharmaceuticals, OncologyBayer, Orion Corp, prostate cancer, ARASENS (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 3, 2016 Category: Pharmaceuticals Source Type: news

Genetic biomarker may predict nerve pain side effects associated with prostate cancer treatment
Taxanes are a group of drugs commonly used to treat cancers of the breast, lung, ovary, or prostate, but its use can be limited by significant side effects. Researchers report prostate cancer patients who have a variation in the VAC14 gene are more susceptible to a side effect called peripheral neuropathy when treated with the taxane docetaxel. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 13, 2016 Category: Science Source Type: news

Genetic biomarker may predict nerve pain side effects associated with prostate cancer treatment
(H. Lee Moffitt Cancer Center & Research Institute) Taxanes are a group of drugs commonly used to treat cancers of the breast, lung, ovary, or prostate, but its use can be limited by significant side effects. Researchers from Moffitt Cancer Center report prostate cancer patients who have a variation in the VAC14 gene are more susceptible to a side effect called peripheral neuropathy when treated with the taxane docetaxel. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 13, 2016 Category: Global & Universal Source Type: news

Prognostic Factors, Risk Stratification in CRPC on DocetaxelPrognostic Factors, Risk Stratification in CRPC on Docetaxel
Could certain prognostic factors help predict overall survival in castration-resistant prostate cancer patients treated with docetaxel? BMC Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Tumor Marker Role in Metastatic Prostate CancerTumor Marker Role in Metastatic Prostate Cancer
A tumor marker in peripheral blood may help determine which men with metastatic castration-resistant prostate cancer (mCRPC) respond well to docetaxel and which will benefit from a different therapy, researchers from Spain suggests. Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - March 21, 2016 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Where Prostate Cancer Spreads In the Body Affects Survival Time
Contact: Sarah Avery Phone: 919-660-1306 Email: sarah.avery@duke.edu https://www.dukehealth.org EMBARGOED FOR RELEASE until 4 p.m. (ET) on Monday, March 7, 2016 DURHAM, N.C. -- Patients with lymph-only metastasis have the longest overall survival, while those with liver involvement fare worst. Lung and bone metastasis fall in the middle. “Smaller studies had given doctors and patients indications that the site of metastasis in prostate cancer affects survival, but prevalence rates in organ sites were small, so it was difficult to provide good guidance,” said Susan Halabi, Ph.D., professor of biostatistics ...
Source: DukeHealth.org: Duke Health Features - March 8, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news

Combo Tx Boosts PFS in Urothelial Cancer (CME/CE)
(MedPage Today) -- Progression slowed by half with docetaxel and anti-VEGF agent (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 3, 2016 Category: Hematology Source Type: news

How and When Does Taxotere (Docetaxel) Work to...
Taxotere (docetaxel) is a drug used in men whose prostate cancer no longer responds to hormone therapy. (Source: About.com Prostate Cancer)
Source: About.com Prostate Cancer - January 26, 2016 Category: Cancer & Oncology Tags: health Source Type: news

Athenex Announces US FDA Allowance of the Investigation New Drug Application of Oradoxel, the Proprietary Oral Form of Docetaxel
BUFFALO, N.Y. and HONG KONG, Jan. 25, 2016 -- (Healthcare Sales & Marketing Network) -- Athenex, Inc. announced today that it has received United States Food and Drug Administration (US FDA) allowance to proceed in the clinic with its proprietary oral for... Biopharmaceuticals, Oncology, FDAAthenex, Docetaxel, Orascovery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 25, 2016 Category: Pharmaceuticals Source Type: news

Even After Anti-Androgen Therapy, Docetaxel Remains Useful in Prostate...
University of Colorado Cancer Center and collaborating institutions present results at 2016 Genitourinary Cancers Symposium showing that 40 percent of patients with castration-resistant metastatic...(PRWeb January 12, 2016)Read the full story at http://www.prweb.com/releases/2016/01/prweb13159325.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 14, 2016 Category: Pharmaceuticals Source Type: news

Even after anti-androgen therapy, docetaxel remains useful in prostate cancer
40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 11, 2016 Category: Science Source Type: news

Even after anti-androgen therapy, docetaxel remains useful in prostate cancer
(University of Colorado Anschutz Medical Campus) A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 10, 2016 Category: Cancer & Oncology Source Type: news